2008 Annual Meeting | Diagnosis and Management of Motor Neuron Disease: Spinal Muscular Atrophy

Date Saturday 04/12/08

Time 06:00 PM - 08:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Kick-Off Program

Director(s) Hiroshi Mitsumoto, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with up-to-date knowledge of the disease entity of SMA and understand how to make a correct diagnosis; gain practical knowledge on how to manage patients with SMA in different age groups; and become familiar with the current state of SMA clinical trials.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
06:00 PM - 08:00 PM		Diagnosis and Management of Motor Neuron Disease: SMA Susan T. Iannaccone, MD, FAAN, Petra Kaufmann, MD, FAAN, Hiroshi Mitsumoto, MD, FAAN
06:00 PM - 08:00 PM		Reception

Faculty Disclosures
Hiroshi Mitsumoto, MD, FAAN	Dr. Mitsumoto has nothing to disclose.
Petra Kaufmann, MD, FAAN	Dr. Kaufmann has received personal compensation for serving as an employee of Affinia Therapeutics. Dr. Kaufmann has received personal compensation for serving as an employee of Vigil Neuroscience. Dr. Kaufmann has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for DTx. Dr. Kaufmann has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Taysha Gene Therapies. Dr. Kaufmann has stock in Vigil Neuroscience. The institution of an immediate family member of Dr. Kaufmann has received research support from Cystic Fibrosis Foundation . Dr. Kaufmann has a non-compensated relationship as a Member of a Scientific Advisory Board with NIH that is relevant to AAN interests or activities.
Susan T. Iannaccone, MD, FAAN	Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AveXis. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AveXis. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Iannaccone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catabasis. The institution of Dr. Iannaccone has received research support from AveXis. The institution of Dr. Iannaccone has received research support from Biogen. The institution of Dr. Iannaccone has received research support from Sarepta. The institution of Dr. Iannaccone has received research support from PTC Therapeutics. The institution of Dr. Iannaccone has received research support from FibroGen. The institution of Dr. Iannaccone has received research support from ReveraGen. The institution of Dr. Iannaccone has received research support from MDA. The institution of Dr. Iannaccone has received research support from PPMD. The institution of Dr. Iannaccone has received research support from NIH. Dr. Iannaccone has received personal compensation in the range of $0-$499 for serving as a grant reviewer with NIH.

��ɫ��

��ɫ��